# Cirrhosis

---

## I. Purpose

Patients with cirrhosis who require emergency general surgery have significantly higher morbidity and mortality rates than patients without cirrhosis[^1]. While data on outcomes and risk prognostication remain limited in this population, this document outlines perioperative management considerations for the cirrhotic patient.

---

## II. Guideline

### A. Initial Evaluation of the Cirrhotic Patient with EGS Pathology

- **Liver disease stratification scores**
    
    * MELD 3.0: INR, total bilirubin, creatinine, albumin, sodium, age, sex  
    * Child-Pugh: INR, total bilirubin, albumin, ascites, hepatic encephalopathy

- **Imaging review**
    
    * Evaluate for sequelae of portal hypertension: abdominal wall varices, splenomegaly, ascites

- **Postoperative risk scores**
    
    * Patients with MELD >20 or Child-Pugh class C have high risk of postoperative decompensation and death  
    * No absolute cutoff excludes patients from surgery; individualized prognostication recommended  
    * Risk calculators:
        * POTTER: [Apple App Store](https://apps.apple.com/us/app/potter/id1364985773)  
        * Mayo Postoperative Mortality Risk Score: [Mayo Clinic Tool](https://www.mayoclinic.org/medical-professionals/transplant-medicine/calculators/post-operative-mortality-risk-in-patients-with-cirrhosis/itt-20434721)  
        * VOCAL-Penn: [vocalpennscore.com](https://www.vocalpennscore.com/)

---

### B. Preoperative Correction of Coagulopathy

- **INR**
    
    * Do not reverse unless actively bleeding or on vitamin K antagonist[^3]

- **Platelets**
    
    * No transfusion unless active bleeding or platelets <30,000[^4]  
    * Hold DVT prophylaxis if platelets <50,000[^5]

- **Fibrinogen**
    
    * Transfuse cryoprecipitate to maintain >100 before surgery or with active bleeding[^2][^3]

- **TEG (Thromboelastography)**
    
    * Use if available to direct transfusions and minimize blood product use[^6]

---

### C. Cholecystitis in the Cirrhotic Patient

- **Imaging**
    
    * RUQ US may show wall thickening or pericholecystic fluid due to portal hypertension  
    * HIDA scan if ultrasound/CT non-diagnostic[^7]  
    * MRCP if HIDA is non-diagnostic or biliary obstruction is suspected

- **Treatment**
    
    * MELD ≤13 or Child-Pugh A/B:
        * Antibiotics + laparoscopic cholecystectomy[^8][^9]
    
    * MELD >13 or Child-Pugh C or decompensated:
        * Do not offer cholecystectomy  
        * Begin antibiotics  
        * If no improvement, consult IR + GI for cholecystostomy vs advanced endoscopy[^8][^10]  
            * Avoid percutaneous approach if ascites present
    
- **Transplant Surgery Referral**
    
    * For patients listed for transplant, with history of HCC, or with a TIPS

---

### D. Postoperative Management

- **Hepatic Encephalopathy**
    
    * Resume home regimen if chronic  
    * If new:
        * Check ammonia level (no need to trend)  
        * Start lactulose 20g or 30mL PO BID–TID to 2–3 BMs/day[^11]  
        * Add rifaximin 550mg PO BID if needed  
        * If NPO: use lactulose enemas q4–6 hours  
        * Hepatology consult if refractory

- **Ascites**
    
    * Diuretics
        * Resume when hemodynamically stable  
        * If starting new:
            * Spironolactone 100mg PO daily → up to 400mg  
            * Furosemide 40mg PO daily → up to 160mg[^12]
    
    * If surgical drain present:
        * Empty every 4 hours x 72h  
        * Remove ASAP after 72h if ascites controlled[^11]  
        * Replace albumin: 6g of 25% albumin per liter drained  
        * SBP prophylaxis if intra-abdominal sepsis covered:
            * PO: Ciprofloxacin 500mg daily  
            * IV: Ceftriaxone 1g daily
    
    * If no drain:
        * Consider large-volume paracentesis (LVP)
            * Indications:
                * Ascites leak from surgical site  
                * Suspected peritonitis  
                * Diuretics contraindicated  
            * Albumin: 6–8g 25% per liter if >5L removed[^11]
    
    * Hepatology consult if unresponsive

- **Prophylactic Anticoagulation**
    
    * Start if platelets >50,000[^5]  
    * CrCl >30: Enoxaparin 40mg SC daily  
    * CrCl <30: Heparin 5,000u SC q8h

- **Fluid Management**
    
    * Use balanced crystalloids (e.g., LR, Plasmalyte) to reduce hyperchloremia[^11]

- **Postop Medications**
    
    * **Opiates** (reduced dose/frequency):
        * Oxycodone 2.5–5mg q6h  
        * Hydromorphone 0.125–0.25mg IV q6h
    
    * **Acetaminophen** safe up to 2g/day[^2]:
        * 500mg q6h or 650mg TID
    
    * **Avoid**:
        * NSAIDs (renal injury)[^2]  
        * Benzodiazepines (hepatic clearance)[^2]

- **SBP Prophylaxis**
    
    * Indications:
        * Resumption of home SBP prophylaxis  
        * Intraperitoneal drain in place[^13]  
        * High-risk patients[^14]:
            * Prior SBP  
            * Ascites protein <1.5g/L  
            * Child-Pugh C  
            * Renal dysfunction (Cr >1.2, BUN >25, Na <130)  
            * Active GI bleed
    
    * Therapy:
        * PO: Ciprofloxacin 500mg q24h  
        * IV: Ceftriaxone 1g q24h if NPO[^2]

---

### E. Indications for Perioperative Hepatology Consult

- Management of decompensated cirrhosis (e.g., refractory ascites, encephalopathy, GI bleeding)
- TIPS evaluation for refractory ascites
- Liver transplant evaluation (e.g., acute liver failure)
- Long-term management of portal vein thrombosis

---

## III. References

[^1]: Bleszynski MS, et al. *World J Emerg Surg.* 2018;13:32.  
[^2]: Northup PG, et al. *Clin Gastroenterol Hepatol.* 2019;17(4):595–606.  
[^3]: Kaltenbach MG, Mahmud N. *Hepatol Commun.* 2023;7(4).  
[^4]: Northup PG, et al. *Hepatology.* 2021;73(1):366–413.  
[^5]: Simonetto DA, et al. *Am J Gastroenterol.* 2020;115(1):18–40.  
[^6]: De Pietri L, et al. *Hepatology.* 2016;63(2):566–573.  
[^7]: Ziessman HA. *Clin Gastroenterol Hepatol.* 2010;8(2):111–116.  
[^8]: Wang SY, et al. *Gut Liver.* 2021;15(4):517–527.  
[^9]: Delis S, et al. *Surg Endosc.* 2010;24(2):407–412.  
[^10]: Hanna K, et al. *Am J Surg.* 2023;226(5):668–674.  
[^11]: Seshadri A, et al. *Trauma Surg Acute Care Open.* 2022;7(1):e000936.  
[^12]: Aithal GP, et al. *Gut.* 2021;70(1):9–29.  
[^13]: Macken L, et al. *Frontline Gastroenterol.* 2022;13(e1):e116–e125.  
[^14]: Biggins SW, et al. *Hepatology.* 2021;74(2):1014–1048.

---

## IV. Authors

- Stefanie P. Lazow, MD  
- Michael C. Smith, MD  
- Michael Derickson, MD  
- Andrew Medvecz, MD  

*October 28, 2024*
